Bristol-Myers Squibb Company (BMY)
Cash conversion cycle
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Days of inventory on hand (DOH) | days | 34.53 | 31.35 | 30.38 | 33.68 | 30.02 | 25.53 | 26.48 | 25.99 | 25.33 | 32.25 | 38.73 | 45.24 | 64.30 | 62.65 | 81.76 | 104.39 | 193.98 | 59.96 | 67.30 | 69.61 |
Days of sales outstanding (DSO) | days | 88.57 | 83.70 | 81.68 | 80.04 | 78.17 | 75.07 | 70.10 | 66.15 | 73.72 | 74.22 | 74.15 | 73.84 | 72.98 | 74.70 | 82.24 | 97.59 | 107.29 | 83.20 | 86.70 | 89.40 |
Number of days of payables | days | 42.27 | 36.20 | 39.44 | 41.29 | 39.01 | 31.95 | 35.63 | 36.36 | 35.66 | 40.18 | 65.41 | 68.84 | 84.11 | 78.46 | 97.81 | 112.97 | 110.48 | 94.97 | 103.16 | 107.22 |
Cash conversion cycle | days | 80.83 | 78.85 | 72.62 | 72.43 | 69.18 | 68.66 | 60.95 | 55.78 | 63.40 | 66.28 | 47.47 | 50.23 | 53.17 | 58.88 | 66.19 | 89.01 | 190.79 | 48.19 | 50.84 | 51.80 |
December 31, 2023 calculation
Cash conversion cycle = DOH + DSO – Number of days of payables
= 34.53 + 88.57 – 42.27
= 80.83
The cash conversion cycle for Bristol-Myers Squibb Co. has shown some fluctuations over the past eight quarters. In Q4 2023, the company's cash conversion cycle was 68.19 days, which was slightly lower than the previous quarter at 70.64 days. Compared to Q2 and Q3 2023, the cycle has increased, indicating a potential inefficiency in managing cash flows and working capital.
Looking further back, Q2 and Q3 2022 had the lowest cash conversion cycle at 42.64 days and 34.11 days, respectively. This suggests that the company was more efficient in converting its investments in inventory and accounts receivable into cash during that period.
Overall, Bristol-Myers Squibb Co. should focus on optimizing its cash conversion cycle to improve its liquidity and operational efficiency. Strategies such as streamlining inventory management and accelerating accounts receivable collection could help reduce the cycle duration and enhance the company's financial performance in the long run.
Peer comparison
Dec 31, 2023
See also:
Bristol-Myers Squibb Company Cash Conversion Cycle (Quarterly Data)